Skip to main content

Advertisement

Table 6 Proportions of adverse events by treatment group

From: Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India

Event (MedDRA Preferred Term)1 DP n (%) A + M n (%)
At least one AE 60 (59.4%) 33 (67.4%)
Anaemia 6 (5.9%) 4 (8.2%)
Asthenia 10 (9.9%) 9 (18.4%)
Pyrexia 18 (17.8%) 10 (20.4%)
Malaria2 5 (5.0%) 7 (14.3%)
Eosinophil count increased 13 (12.9%) 2 (4.1%)
Haematocrit decreased 11 (10.9%) 5 (10.2%)
Haemoglobin decreased 13 (12.9%) 7 (14.3%)
Red blood cell count decreased 11 (10.9%) 10 (20.4%)
At least one SAE 5 (5.0%) 1 (2.0%)
At least one drug-related SAE 4 (4.0%) 1 (2.0%)
  1. AE, adverse event; SAE serious adverse event; DP, dihydroartemisinin-piperaquine; A + M, artesunate-mefloquine.
  2. 1Shown are Adverse Events with a frequency > 5%.
  3. 2Reporting of malaria as an adverse event was not complete in this study. Some study centres chose not to report malaria as it was known that to enter the study all patients had to have Plasmodium falciparum infection.